Signadori Bio
Next-gen solid tumor immunotherapy platform
About
Signadori Bio, founded in 2025 in Paris, France, develops next-generation solid tumor immunotherapies by engineering monocytes. Originating from a proprietary platform at Institut Gustave Roussy, Europe's largest cancer center, their approach focuses on innovative cell therapy to treat solid tumors. Backed by Sofinnova Partners and Invivo Partners, the company advances its monocyte engineering platform through seed funding to develop breakthrough therapeutics for oncology. Signadori Bio operates a biopharma business model focusing on R&D and clinical development targeting cancer treatment.
Products
-
Monocyte Engineering Platform
— Proprietary cell therapy platform engineering monocytes to target and treat solid tumors.
Customer sectors: oncology pharmaceutical companies, biotech investors
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Signadori Bio — available to members.
Related Companies
Other startups in Biotech & Therapeutics
